## Data sources for natural clearance of chlamydia infection in men

## Joanna Lewis

## References

- [1] Handsfield HH, Alexander ER, Wang SP, Pedersen AHB, Holmes KK. Differences in the Therapeutic Response of Chlamydia-Positive and Chlamydia-Negative Forms of Nongonococcal Urethritis. Journal of the American Venereal Disease Association. 1976;2:5–9.
- [2] Prentice MJ, Taylor-Robinson D, Csonka GW. Non-specific urethritis A placebo-controlled trial of minocycline in conjunction with laboratory investigations. British Journal of Venereal Diseases. 1976;52:269–275.
- [3] Johannisson G, Sernryd A, Lycke E. Susceptibility of Chlamydia trachomatis to Antibiotics in Vitro and in Vivo. Sexually Transmitted Diseases. 1979;6:50–57.
- [4] Paavonen J, Kousa M, Saikku P, Vartiainen E, Kanerva L, Lassus A. Treatment of nongonococcal urethritis with trimethoprim-sulphadiazine and with placebo: A double-blind partner-controlled study. British Journal of Venereal Diseases. 1980;56:101–4.
- [5] Joyner JL, Douglas JM, Foster M, Judson FN. Persistence of Chlamydia trachomatis Infection Detected by Polymerase Chain Reaction in Untreated Patients. Sexually Transmitted Diseases. 2002;29:196–200.
- [6] Geisler WM, Wang C, Morrison SG, Black CM, Bandea CI, Hook EW. The Natural History of Untreated Chlamydia trachomatis Infection in the Interval Between Screening and Returning for Treatment. Sexually Transmitted Diseases. 2008;35:119–123.
- [7] Stamm WE, Cole B. Asymptomatic Chlamydia trachomatis Urethritis in Men. Sexually Transmitted Diseases. 1986;13:163–165.
- [8] van den Brule AJC, Munk C, Winther JF, Kjaer SK, Jørgensen HO, Meijer CJLM, et al. Prevalence and persistence of asymptomatic Chlamydia trachomatis infections in urine specimens from Danish male military recruits. International Journal of STD and AIDS. 2002;13:19–22.

[9] Price MJ, Ades AE, Angelis DD, Welton NJ, Macleod J, Soldan K, et al. Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection. Statistics in Medicine. 2013;32:1547–1560.

First author (year)	Study design	Number clearing	Number tested	Follow-up period	Estimated mean
		infection	at follow-up		follow-up (years)
Handsfield (1976) [1]	Clinic	0	10	1 week	0.019
	Culture				
Prentice (1976) [2]	Clinic	4	13	(7-21) days;	0.023
	Culture			mean 8.5 days	
Johannisson (1979) [3]	Clinic	3	17	1 week	0.019
	Culture	13	27	2 weeks	0.038
		3	6	3 weeks	0.058
		2	2	4 weeks	0.077
Paavonen (1980) [4]	Clinic	7	21	4 weeks	0.077
	Culture				
Joyner (2002) [5]	Clinic	3	15	0-(2-7)  days	0.012
	NAATs	2	9	0-(8-14)  days	0.030
		1	4	0-(15-21)  days	0.049
		0	4	0-(22-42)  days	0.088
		1	4	0-(43-112)  days	0.190
Geisler (2008) [6]	Clinic	5	14	0-(4-59) days*	0.045
	NAATs				
Stamm (1986) [7]	Clinic-based screening	1	5	1 week	0.019
	Culture	0	2	2 weeks	0.038
		0	2	3 weeks	0.058
		0	1	4 weeks	0.077
van den Brule (2002)	Screening	1	9	6 months	0.5
[8]	NAAT				

 $<sup>^{\</sup>ast}$  Follow-up period for men and women combined.

Table 1: Data sources for duration of an untreated, uncomplicated, asymptomatic episode of chlamydia in men. Analagous to evidence collected for women in [9].